Clinical trials: Antipsychotic
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Energy Homeostasis Under Treatment With Atypical Antipsychotics
The purpose of this study is to evaluate the effects of different atypical antipsychotics on weight changes, energy homeostasis, metabolism, energy intake as well as activity.
- Trial name
- NCT00148564
- Testing
- olanzapine, Ziprasidone
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia.
- Trial name
- NCT00862992
- Testing
- Cariprazine 3 mg, Cariprazine 6 mg, Cariprazine 12.5 mg
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Tanabe Pharma Corporation
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Delirium
Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery
In this study we wanted to determine if perioperative administration of olanzapine prior to knee or hip replacement surgery in high risk patients would prevent the onset of postoperative delirium.
- Trial name
- NCT00699946
- Testing
- olanzapine
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- The New England Baptist Hospital
Brain Insulin Sensitivity, Healthy Controls
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
This study aimed at helping researchers understand how a medication called haloperidol can affect insulin action in the brain. Insulin is a hormone in the body that controls sugar levels in part by lowering the amount of glucose…
- Conditions
- Brain Insulin Sensitivity, Healthy Controls, Cognition
- Trial name
- NCT07109245
- Testing
- Haloperidol, Insulin Lispro, Saline
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Mental Illness
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
This study will evaluate the effectiveness of a cognitive behavioral treatment in reducing significant medical risk factors often associated with people who have a serious mental illness and are taking atypical antipsychotic…
- Trial name
- NCT00709345
- Testing
- Cognitive behavioral sessions, Time-matched attention control sessions
- Volunteers
- 333 people
- Sponsor
- Medical College of Wisconsin
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability.
- Conditions
- Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- DREAMS-Phen (NCT07152184)
- Testing
- Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup
- Volunteers
- 288 people
- Sponsor
- University Hospital, Strasbourg, France
Autistic Disorder
A Controlled Study of Olanzapine in Children With Autism
This is a 12-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 3 to 12 years old.
- Trial name
- NCT00057408
- Testing
- olanzapine (Zyprexa)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- FDA Office of Orphan Products Development
Schizophrenia
Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.
- Trial name
- NCT00763438
- Testing
- Sertindole
- Where
- France
- Volunteers
- 18 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
A Study in the Treatment of Acute Mania
The purpose of this study is to test the efficacy and total costs of olanzapine versus commonly used conventional antipsychotics in Sweden.
- Trial name
- NCT00767715
- Testing
- olanzapine, haloperidol, zuclopentixol
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder
This prospective study examines the differences among several measures of adherence to antipsychotic medications in outpatients with schizophrenia.
- Trial name
- MEMS-SPR (NCT00861003)
- Testing
- Medication Event Monitoring System (MEMS)
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Korea University Guro Hospital
Schizophrenia, Schizoaffective Disorder
Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
Background: Antipsychotics can induce metabolic disorders such as obesity, hyperglycemia, dyslipidemia or metabolic syndrome. It has been observed that treatment with antipsychotic could be accompanied by a decrease in the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT02986490
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Schizophrenia, Psychotic Disorders
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline
- Trial name
- NCT00137020
- Testing
- ziprasidone
- Where
- 27 sites in Egypt, Greece and 7 more
- Volunteers
- 294 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
C-Cog in Early Course Schizophrenia Study
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
- Trial name
- NCT05662306
- Testing
- Aripiprazole Lauroxil, Computerized cognitive and functional skills training
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Dementia
Improving Well-being and Health for People With Dementia
800,000 people in the United Kingdom (UK)have dementia, of which 250,000 are living in care homes. These individuals have complex mental health problems, disabilities and social needs, which if unmet will continue to adversely…
- Trial name
- WHELD (NCT01855152)
- Testing
- Optimised WHELD intervention, Treatment as usual
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- professor Clive Ballard
Bipolar I Disorder
Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
Hypothesis: Continuation of an atypical antipsychotic medication in combination with a Mood Stabilizer, following remission from an acute manic episode, lowers the rates of relapse and recurrence of mood episodes compared to…
- Trial name
- NCT01977300
- Testing
- Valproate, Lithium, Risperidone
- Where
- Canada
- Volunteers
- 159 people
- Sponsor
- University of British Columbia
Obsessive-Compulsive Disorder
Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder
This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.
- Trial name
- NCT00389493
- Testing
- Risperidone, Exposure/ritual prevention therapy (EX/RP)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute